On 9 November 2020, Pfizer announced that its experimental COVID-19 vaccine has more than 90% efficacy. The initial positive results of the clinical trial demonstrated its efficacy. This is indeed a significant triumph in the battle against a virus that has led to the death of several people and has considerably impaired the economy.

The public healthcare officials, scientists, and investors greeted the first successful interim data from a large-scale test that could aid turn the pandemic if the complete trial findings pan out. However, mass roll-outs, which requires regulatory approval, will not happen this year and numerous vaccines are seen as essential to fulfill the massive global requirements.

No critical safety concerns were witnessed. Pfizer anticipates getting Unites States (U.S.) emergency use authorization in November, increasing the likelihood of a regulatory decision in December.

It is anticipated that up to 50 million doses can be rolled out in 2020 that is enough to safeguard 25 million people, and about 1.3 billion doses can be developed in 2021.

The preliminary outcomes of the clinical trial looked promising. It is a great relief to observe such promising outcomes on this vaccine. There are still multiple questions, such as how effective this vaccine is by age or ethnicity and how long the immunity may last.

Pfizer anticipates getting U.S. emergency use authorization for individuals aged 16-85 years. To accomplish it, it will require 2 months of follow-up safety data to ascertain that no adverse events crop up. This is anticipated to be available in November's third week. It would take many weeks for U.S. regulators to procure and process the data prior to the approval.